Symbols

DMRA

Damora Therapeutics·NASDAQ

--(--)

DMRA Profile

Damora Therapeutics, Inc.

An innovative biotechnology company focused on redefining treatment options for patients with hematologic disorders

Industry

Pharmaceutical

Established Date

Listing Date

10/29/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.damoratx.com

Security Type

Common stock

Office address

221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453

Business

Introduction

Damora Therapeutics, Inc., incorporated in Delaware in October 2019, is an innovative biotechnology company focused on redefining treatment options for patients with hematological disorders. The company is advancing the development of a new generation of biologics aimed at treating myeloproliferative tumors driven by mutant calreticulin, including primary thrombocytosis and myelofibrosis, which urgently need treatment options that can improve the condition. Several of Damora's projects demonstrate best-in-class potential and are scheduled to enter clinical development in 2026. The company's goal is to rapidly roll out optimized therapies that not only cover a wide range of mutation types, but are also extremely easy to use, with the ultimate goal of significantly improving patient outcomes.